Daiichi Sankyo Co.’s edoxaban, the latest in a new group of blood thinners aimed at replacing warfarin, was found to be as effective as the drug that has been the standard of care for 60 years, in a study.
Concerns raised by two Harvard researchers over new treatment guidelines for heart risk shouldn’t change the method used for determining what patients should get cholesterol-lowering drugs, top U.S. heart doctors said today at the American Heart Association meeting in Dallas.
A procedure to clear and prop open clogged kidney arteries didn’t offer a cardiovascular benefit to patients more than drug therapy, researchers said, underscoring the need to use medicines first to reduce heart disease.
A new class of cholesterol-lowering medicines from Pfizer Inc. and Amgen Inc. may struggle to meet sales projections, as latest treatment guidelines suggest doctors should prescribe only drugs proven to help the heart.
U.S. regulators won’t require Amgen Inc., Sanofi, Pfizer Inc. and other companies developing the next class of cardiovascular medicines to prove the therapies prevent heart attacks and death before they’re approved.
Millions of Americans going for an annual checkup in 2014 will come away from the doctor’s office with a new prescription to lower their cholesterol, a move cardiologists say will avert heart attacks and strokes.